Satralizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | interleukin 6 receptor |
Clinical data | |
Synonyms | SA237 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
Chemical and physical data | |
Formula | C6340H9776N1684O2022S46 |
Molar mass | 143.4 g/mol |
Satralizumab (SA237, formerly sapelizumab) (INN[1]) is a monoclonal antibody that is being investigated for neuromyelitis optica[2].
This drug is being developed by Chugai Pharma in conjunction with Roche. As of 2018, satralizumab is undergoing Phase III trials.
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.